Transforming GI Cancer and Fibrosis Treatment
Proglumide: A Multi-Indication Platform, with a Regulatory Advantage, & Accelerated Path to Market
Our Science
Executive Summary
- Proglumide is a small molecule repurposed drug with Oral bioavailability and several mechanisms of action including antagonizing the CCK-B receptor.
- Pancreatic Cancer
- Chronic Pancreatitis
- Liver Fibrosis
- Pain Management
- Early Phase 1 Results
- Ongoing Phase 1/2 Trials
- Regulatory Advantages
- Fast-Track Potential
PROGLUMIDE’S UNIQUE MECHANISM OF ACTION
- Dual CCK Receptor Blockade Targeting Oncogenic and Fibrotic Pathways
BREAKTHROUGH PRECISION THERAPY
CCK-A and CCK-B Blockade - Reduces cancer cell proliferation and inflammation, addresses fibrosis at its source.
A FOCUSED APPROACH TO CANCER PROGRESSION
Oncogenic Potential - Targets CCK-B receptors in pancreatic cancer to inhibit tumor growth.
- ADDRESSES FIBROSIS AT ITS CORE
- Fibrosis Reduction - Proglumide induce plasticity on activated fibroblasts to make them quiescent through the CCK-B receptor only. Proglumide also has a receptor-independent effect that breaks down established fibrosis.
INNOVATIVE PATHWAYS IN PAIN MANAGEMENTPain Management Potential - CCK receptor antagonism in the brain shown to reduce opioid dependency, opening additional therapeutic applications.
Our Team
Chris Dunk, CEO
Chris Dunk is the current CEO of the Biotech company Eldyenn Inc and Mall Interactive Telecom. He has years of executive experience founding and managing telecommunication and biotech opportunities. Mr. Dunk has raised millions of dollars in funding for Real Estate, Telecom and Biotech ventures.
.png)
- Lynda Sutton, Cofounder, President, and Chief Regulatory Officer Lynda Sutton, currently serves as the President and Chief Regulatory Officer for Cato Bioventures and President for Cancer Advances as well.
- Ms. Sutton has 40 years of experience in the drug development industry, specializing in the development of regulatory strategies for drugs and biologics.
- She has coordinated activities in various disciplines and has been involved in the development of new clinical entities, has overseen the preparation of FDA pre-meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied.
- She has served as the primary regulatory contact for more than one hundred Biotech and pharmaceutical companies over the last 35 years. In addition, Ms. Sutton has co-founded over ten small biotechnology companies and serves as a member of the board of directors for several companies.
John Wingen, Cofounder and CFO
John Wingen has extensive operational and leadership experience, having served in executive leadership roles for over 45 years. For the last 10 years John has served in finance and operational roles in the drug development industry. John has experience both buying and selling companies and raising investment funds.